Loading...
NPI 1134439573 · Piscataway, NJ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Star Laboratory Corporation is a clinical medical laboratory provider located in Piscataway, New Jersey. This profile covers 55 Medicare and 53 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Star Laboratory Corporation |
| Address | 125 Fleming St |
| City | Piscataway |
| State | NJ |
| ZIP | 08854 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 19, 2010 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $17.7M |
| Medicaid | $11.9M |
STAR LABORATORY CORPORATION operates primarily as a clinical molecular diagnostic laboratory with a heavy emphasis on genetic and genomic testing for Medicare beneficiaries; its top Medicare codes are dominated by high‑complexity molecular sequencing and single‑gene full sequencing tests such as 81419, 81317, and 81307, indicating a service mix centered on advanced genetic diagnostics rather than routine chemistry or hematology panels. The prominence of codes like 81419 (genomic sequencing panels) and multiple single‑gene sequencing CPTs shows an operational focus on specialized, higher‑paid molecular assays.
Medicare revenue is concentrated: the precomputed top‑3 Medicare codes account for 36.8% of this provider’s total Medicare revenue, with 81419 alone contributing $3.1M (19.6% of Medicare revenue). This concentration signals that a relatively small set of advanced genetic tests are a major driver of the provider’s Medicare business and suggests vulnerability to pricing or utilization shifts for those specific codes.
On Medicaid, revenue is even more concentrated: the top‑3 Medicaid codes account for 90.9% of the provider’s total Medicaid revenue, with large volumes in presumptive and definitive drug testing (80307 and G0480) which together represent the majority of Medicaid receipts ($4.9M and $4.8M respectively). This indicates the provider’s Medicaid operations are dominated by drug testing and high‑throughput COVID testing (U0004, U0005), implying different service lines drive Medicaid versus Medicare revenue.
Comparing payer scale, STAR LABORATORY CORPORATION reports $17.7M in total Medicare revenue and $11.9M in total Medicaid revenue, so Medicare is the larger single source though Medicaid is also substantial. The dual‑payer profile shows the lab serves both traditional Medicare genetic testing markets and high‑volume Medicaid drug/COVID testing markets, suggesting diversified payer exposure but different service lines per payer.
Competitive standing on several Medicare codes is strong: the provider ranks #1 nationally for 81419 (100th percentile; described as an "extreme outlier, far above typical national volume for this code") and also ranks at or near the top for other sequencing codes (e.g., 81317 and 81298 at the 96th percentile). These rankings indicate STAR LAB is a leading national performer for selected high‑complexity genomic tests rather than a typical regional lab for those services.
By contrast, its Medicaid positioning is more typical within New Jersey for high‑volume drug testing: 80307 ranks #12 of 151 in‑state (93rd percentile) and G0480 ranks #7 of 110 (94th percentile), reflecting strong but not singular dominance in state Medicaid drug testing markets. The Medicaid ranks imply it is a major in‑state participant for definitive and presumptive drug testing but not necessarily an exclusive provider.
The provider’s claim volumes for many Medicare sequencing codes are unusually high relative to peers (multiple codes flagged as "notably above typical" or extreme), which reinforces a business model built around high throughput genomic assays; several single‑gene sequencing codes also rank in the top deciles nationally, supporting that characterization. This pattern suggests specialized laboratory capacity and likely investments in sequencing platforms and bioinformatics.
STAR LABORATORY CORPORATION has been enumerated since 2010-10-19 (~16 years ago), indicating an established presence in the market; tenure combined with the observed national rank for core genomic codes suggests it has built a sustained niche in molecular diagnostics over more than a decade.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
55 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 1,300 | $2,400 | $3.1M |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 2,100 | $660 | $1.4M |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 2,040 | $660 | $1.4M |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 2,120 | $630 | $1.3M |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 1,830 | $590 | $1.1M |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 1,780 | $590 | $1M |
| 81325 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the peripheral myelin protein 22, or PMP22, gene. | 1,290 | $750 | $968.9K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 1,830 | $490 | $895.8K |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 260 | $1,790 | $459.5K |
| 81201 | The lab analyst performs the technical lab test to analyze the entire gene sequence for adenomatous polyposis coli, also known as APC. | 520 | $760 | $396.5K |
Showing 1–10 of 55
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 55 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
55 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81419 | 1 | 10 | 1,300 | $2,400 | $3.1M |
| 81325 | 2 | 10 | 1,490 | $750 | $1.1M |
| 81238 | 2 | 10 | 1,290 | $590 | $816K |
| 81249 | 2 | 10 | 830 | $590 | $692.2K |
| 81307 | 2 | 10 | 910 | $660 | $635.4K |
| 81317 | 2 | 10 | 60 | $660 | $511.5K |
| 81298 | 2 | 10 | 60 | $630 | $489.5K |
| 81223 | 2 | 10 | 830 | $490 | $467.8K |
| 81189 | 2 | 10 | 1,520 | $270 | $408K |
| 81286 | 2 | 10 | 1,460 | $270 | $392.4K |
Showing 1–10 of 55
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
53 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 111,960 | $40 | $4.9M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 76,630 | $60 | $4.8M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 16,700 | $60 | $1.1M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,610 | $180 | $459.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 14,810 | $20 | $296.3K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,410 | $100 | $143.6K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 10,700 | $10 | $85.6K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,660 | $30 | $54.6K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 490 | $10 | $6.3K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 560 | $10 | $5K |
Showing 1–10 of 53
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
53 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 14 | 30 | 2,020 | $110 | $2M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 12 | 150 | 3,680 | $30 | $1.5M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 21 | 40 | 1,690 | $70 | $1.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 18 | 70 | 4,800 | $50 | $1M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7 | 110 | 1,810 | $50 | $930.1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 15 | 30 | 1,680 | $80 | $883.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 46 | 140 | 5,590 | $20 | $823.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 25 | 30 | 630 | $20 | $687.4K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 138 | 190 | 7,750 | $10 | $466.9K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 114 | 160 | 2,310 | $1 | $395.6K |
Showing 1–10 of 53
Other providers in the same ZIP code as Star Laboratory Corporation, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.